10.11.2014 22:57:10
|
Halozyme Loss Wider Than Estimate, Revenue Misses; Stock Down 8%
(RTTNews) - Halozyme Therapeutics Inc (HALO), a biopharmaceutical company, Monday reported third-quarter net loss of $20.3 million or $0.16 per share compared with a loss of $19.3 million or $0.17 per share last year.
Revenues for the quarter were $14.6 million compared with $16 million in the prior year.
Analysts polled by Thomson Reuters estimated a loss of $0.14 per share on revenues of $16.45 million for the quarter. Analysts' estimates typically exclude special items.
![](https://images.finanzen.at/images/unsortiert/wertpapierdepot-absichern-aktienchart-boerse-750493204-260.jpg)
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Halozyme Therapeutics Inc.mehr Nachrichten
07:01 |
Ausblick: Halozyme Therapeutics vermeldet Zahlen zum jüngsten Quartal (finanzen.net) | |
30.10.24 |
Ausblick: Halozyme Therapeutics öffnet die Bücher zum abgelaufenen Quartal (finanzen.net) |
Analysen zu Halozyme Therapeutics Inc.mehr Analysen
15.11.24 | Halozyme Therapeutics Neutral | JP Morgan Chase & Co. |
Aktien in diesem Artikel
Halozyme Therapeutics Inc. | 56,50 | 0,96% |
|